ST天圣维权持续征集，此类投资者切莫错过

Core Viewpoint - The company Tian Sheng Pharmaceutical has been found guilty of financial misconduct, including inflating profits and failing to disclose related party transactions, leading to a formal administrative penalty from regulators [1][2]. Group 1: Regulatory Actions - The Shanghai Huzi Law Firm, represented by lawyer Liu Peng, has submitted a case to the court for litigation against the company [1]. - On November 8, 2025, Tian Sheng Pharmaceutical announced it received an administrative penalty decision from regulators [1][2]. Group 2: Violations Identified - The company inflated profits by approximately 120 million yuan over the years 2017 and 2018 [3]. - Methods of misconduct included using Taihong Company to extract project funds and inflating procurement costs through a wholly-owned subsidiary to create off-the-books funds [2][3]. - The company failed to disclose its investments in and control over Taihong Company and other related parties controlled by the actual controller Liu Qun, resulting in significant omissions in its annual reports for 2017 and 2018 [2][3]. Group 3: Investor Compensation - Investors who purchased shares between April 23, 2018, and January 8, 2025, and sold or still hold shares after January 9, 2025, may join the compensation efforts [3]. - Investors are advised to prepare relevant transaction documents, such as trading records and account statements, for the legal team to assess eligibility for compensation [3].